Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
36 hedge funds and large institutions have $9.47M invested in Carisma Therapeutics in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 14 closing their positions.
377% more call options, than puts
Call options by funds: $826K | Put options by funds: $173K
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 0.86% → 0.77% (-0.09%)
22% less funds holding
Funds holding: 46 → 36 (-10)
49% less capital invested
Capital invested by funds: $18.8M → $9.47M (-$9.28M)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$171K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$46.4K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$27.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$261K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$261K |
| 3 |
HP
Hikari Power
Tokyo,
Japan
|
-$220K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$176K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$146K |
CARM Hedge Fund Activity: Q1 2020 in Review
36 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2020, worth a combined $9.47M — down 49% from $18.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CARM and 6 opened new positions — a net loss of 8 holders — while 6 trimmed existing stakes and 13 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $171K. The largest seller was Credit Suisse, exiting entirely with an estimated $261K sold.
- 36 institutional investors held Carisma Therapeutics (CARM) as of Q1 2020, down from 46 in Q4 2019.
- Funds reported $9.47M of Carisma Therapeutics stock for Q1 2020, down 49% quarter-over-quarter.
- 6 funds opened new Carisma Therapeutics positions in Q1 2020 and 14 closed out, a net change of -8 holders.
- The largest Carisma Therapeutics buyer in Q1 2020 was Renaissance Technologies, an estimated $171K added.
- The largest Carisma Therapeutics seller in Q1 2020 was Credit Suisse, an estimated $261K sold.
Based on aggregated 13F filings for Q1 2020.